<DOC>
	<DOCNO>NCT02099721</DOCNO>
	<brief_summary>The purpose study demonstrate primary prevention patient one additional risk factor ( 1.5 prevention criterion : syncope/pre-syncope , non-sustained ventricular tachycardia ( NSVT ) , frequent pre-ventricular contraction ( PVCs ) , low leave ventricular ejection fraction ( LVEF ) ) similar risk life-threatening ventricular arrhythmia ( LTVA ) compare secondary prevention patient , would receive similar benefit implantable cardioverter defibrillator ( ICD ) , cardiac resynchronization therapy- defibrillator ( CRT-D ) implant .</brief_summary>
	<brief_title>Improve Sudden Cardiac Arrest Study</brief_title>
	<detailed_description>Devices allow study include Medtronic single , dual , triple chamber defibrillator receive appropriate license regulatory approval commercially available Medtronic geography implant take place . Any market-released , commercially available lead ( ) use study .</detailed_description>
	<mesh_term>Heart Arrest</mesh_term>
	<mesh_term>Death , Sudden , Cardiac</mesh_term>
	<criteria>Subject Class I indication implantation ICD accord ACC/AHA/HRS ESC Guidelines Subject ( subject 's legally authorize representative ) willing able sign date Patient Informed Consent Form . Subject â‰¤ 18 year age Subject exclusion criterion require local law ( e.g. , age , pregnancy , breast feed ) Subject enrol concurrent study approve concurrent enrollment Medtronic Clinical Trial Leader Subject contraindication ICD/CRTD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Sudden Cardiac Arrest ( SCA )</keyword>
	<keyword>Syncope</keyword>
	<keyword>NSVT</keyword>
	<keyword>PVC</keyword>
	<keyword>LVEF</keyword>
	<keyword>Primary Prevention</keyword>
	<keyword>Secondary Prevention</keyword>
	<keyword>ATP</keyword>
	<keyword>shock</keyword>
	<keyword>appropriate therapy</keyword>
</DOC>